Andy Chen
Stock Analyst at Wolfe Research
(3.50)
# 915
Out of 5,090 analysts
42
Total ratings
52%
Success rate
30.09%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Andy Chen
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ARGX argenx SE | Downgrades: Peer Perform | n/a | $916.31 | - | 3 | Nov 24, 2025 | |
| NTLA Intellia Therapeutics | Downgrades: Peer Perform | n/a | $9.77 | - | 3 | Nov 12, 2025 | |
| APLS Apellis Pharmaceuticals | Initiates: Peer Perform | n/a | $22.05 | - | 1 | Nov 6, 2025 | |
| AKRO Akero Therapeutics | Downgrades: Peer Perform | n/a | $54.59 | - | 2 | Oct 10, 2025 | |
| ALNY Alnylam Pharmaceuticals | Upgrades: Peer Perform | n/a | $464.56 | - | 3 | Aug 4, 2025 | |
| VERA Vera Therapeutics | Downgrades: Peer Perform | n/a | $42.61 | - | 2 | Aug 4, 2025 | |
| BBIO BridgeBio Pharma | Initiates: Outperform | $49 | $74.74 | -34.44% | 1 | Jun 17, 2025 | |
| SRPT Sarepta Therapeutics | Initiates: Peer Perform | n/a | $22.81 | - | 1 | Jun 17, 2025 | |
| RNA Avidity Biosciences | Initiates: Outperform | $55 | $71.53 | -23.11% | 1 | Jun 17, 2025 | |
| MLTX MoonLake Immunotherapeutics | Upgrades: Outperform | $61 | $15.08 | +304.64% | 3 | May 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $43.05 | - | 1 | Feb 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Peer Perform | n/a | $47.47 | - | 1 | Feb 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $20 | $30.94 | -35.36% | 1 | Feb 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $19 | $37.75 | -49.67% | 1 | Feb 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Peer Perform | n/a | $22.94 | - | 2 | Jan 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $100.48 | - | 1 | Oct 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Peer Perform | n/a | $29.59 | - | 3 | Sep 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $65 | $66.56 | -2.34% | 2 | Aug 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $591.06 | - | 1 | Jun 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $32.49 | - | 1 | Jun 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Peer Perform | n/a | $34.40 | - | 3 | May 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $81.64 | - | 1 | Apr 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Peer Perform | n/a | $58.85 | - | 1 | Feb 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $17 | $21.18 | -19.72% | 1 | Feb 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $457.26 | - | 1 | Feb 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $42 | $205.04 | -79.52% | 1 | Feb 15, 2024 |
argenx SE
Nov 24, 2025
Downgrades: Peer Perform
Price Target: n/a
Current: $916.31
Upside: -
Intellia Therapeutics
Nov 12, 2025
Downgrades: Peer Perform
Price Target: n/a
Current: $9.77
Upside: -
Apellis Pharmaceuticals
Nov 6, 2025
Initiates: Peer Perform
Price Target: n/a
Current: $22.05
Upside: -
Akero Therapeutics
Oct 10, 2025
Downgrades: Peer Perform
Price Target: n/a
Current: $54.59
Upside: -
Alnylam Pharmaceuticals
Aug 4, 2025
Upgrades: Peer Perform
Price Target: n/a
Current: $464.56
Upside: -
Vera Therapeutics
Aug 4, 2025
Downgrades: Peer Perform
Price Target: n/a
Current: $42.61
Upside: -
BridgeBio Pharma
Jun 17, 2025
Initiates: Outperform
Price Target: $49
Current: $74.74
Upside: -34.44%
Sarepta Therapeutics
Jun 17, 2025
Initiates: Peer Perform
Price Target: n/a
Current: $22.81
Upside: -
Avidity Biosciences
Jun 17, 2025
Initiates: Outperform
Price Target: $55
Current: $71.53
Upside: -23.11%
MoonLake Immunotherapeutics
May 19, 2025
Upgrades: Outperform
Price Target: $61
Current: $15.08
Upside: +304.64%
Feb 4, 2025
Initiates: Outperform
Price Target: n/a
Current: $43.05
Upside: -
Feb 4, 2025
Initiates: Peer Perform
Price Target: n/a
Current: $47.47
Upside: -
Feb 4, 2025
Initiates: Outperform
Price Target: $20
Current: $30.94
Upside: -35.36%
Feb 4, 2025
Initiates: Outperform
Price Target: $19
Current: $37.75
Upside: -49.67%
Jan 3, 2025
Downgrades: Peer Perform
Price Target: n/a
Current: $22.94
Upside: -
Oct 1, 2024
Initiates: Outperform
Price Target: n/a
Current: $100.48
Upside: -
Sep 27, 2024
Downgrades: Peer Perform
Price Target: n/a
Current: $29.59
Upside: -
Aug 26, 2024
Upgrades: Outperform
Price Target: $65
Current: $66.56
Upside: -2.34%
Jun 11, 2024
Initiates: Outperform
Price Target: n/a
Current: $591.06
Upside: -
Jun 11, 2024
Initiates: Outperform
Price Target: n/a
Current: $32.49
Upside: -
May 14, 2024
Downgrades: Peer Perform
Price Target: n/a
Current: $34.40
Upside: -
Apr 10, 2024
Upgrades: Outperform
Price Target: n/a
Current: $81.64
Upside: -
Feb 15, 2024
Initiates: Peer Perform
Price Target: n/a
Current: $58.85
Upside: -
Feb 15, 2024
Initiates: Outperform
Price Target: $17
Current: $21.18
Upside: -19.72%
Feb 15, 2024
Initiates: Outperform
Price Target: n/a
Current: $457.26
Upside: -
Feb 15, 2024
Initiates: Outperform
Price Target: $42
Current: $205.04
Upside: -79.52%